Russell Investments Group, Ltd. Igm Biosciences, Inc. Transaction History

Russell Investments Group, Ltd.

$69.8 Billion
Q4 2024

A detailed history of Russell Investments Group, Ltd. transactions in Igm Biosciences, Inc. stock. As of the latest transaction made, Russell Investments Group, Ltd. holds 131 shares of IGMS stock, worth $175. This represents 0.0% of its overall portfolio holdings.

Number of Shares

131

Previous 921 85.78%

Holding current value

$175

Previous $15,000 100.0%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 13, 2025	SELL	$6.05 - $17.83 $4,779 - $14,085	-790 Reduced 85.78%	131 $0
Q3 2024 Nov 13, 2024	BUY	$6.28 - $17.68 $1,155 - $3,253	184 Added 24.97%	921 $15,000
Q2 2024 Aug 08, 2024	BUY	$6.51 - $11.47 $4,309 - $7,593	662 Added 882.67%	737 $5,000
Q4 2023 Feb 05, 2024	SELL	$3.94 - $8.79 $82 - $184	-21 Reduced 21.88%	75 $0
Q3 2023 Nov 13, 2023	BUY	$6.66 - $10.64 $639 - $1,021	96 New	96 $0
Q1 2022 May 05, 2022	SELL	$13.42 - $29.73 $340,129 - $753,506	-25,345 Closed	0 $0
Q4 2021 Jan 21, 2022	SELL	$27.59 - $66.39 $260,891 - $627,783	-9,456 Reduced 27.17%	25,345 $742,000
Q3 2021 Nov 08, 2021	BUY	$65.76 - $90.65 $57,474 - $79,228	874 Added 2.58%	34,801 $2.29 Million
Q2 2021 Aug 04, 2021	BUY	$57.98 - $96.6 $1.45 Million - $2.41 Million	24,998 Added 279.96%	33,927 $2.82 Million
Q1 2021 May 10, 2021	SELL	$71.56 - $121.23 $195,072 - $330,472	-2,726 Reduced 23.39%	8,929 $684,000
Q4 2020 Feb 08, 2021	BUY	$47.41 - $115.03 $552,563 - $1.34 Million	11,655 New	11,655 $1.03 Million

Others Institutions Holding IGMS

# of Institutions

Shares Held

19.5M

Call Options Held

61.3K

Put Options Held

36.7K

View Full List

About IGM Biosciences, Inc.

Ticker IGMS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,969,000
Market Cap $38.8M
Description
IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non...

More about IGMS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Russell Investments Group, Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Russell Investments Group, Ltd. with notifications on news.

Account

Russell Investments Group, Ltd. Igm Biosciences, Inc. Transaction History